Quantcast
Home > Quotes > SRRA

Sierra Oncology, Inc. Common Stock (SRRA) Quote & Summary Data

SRRA 
$3.3
*  
0.14
4.07%
Get SRRA Alerts
*Delayed - data as of Jun. 22, 2018  -  Find a broker to begin trading SRRA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.45 / $ 3.27
Share Volume
308,737
50 Day Avg. Daily Volume
600,662
Previous Close
$ 3.44
52 Week High / Low
$ 4.09 / $ 1.115
Market Cap
245,227,887
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
308,737
50 Day Avg. Daily Volume:
600,662

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.78

Trading Range

The current last sale of $3.30 is 195.96% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.45 $ 4.09
 Low: $ 3.27 $ 1.115

Company Description (as filed with the SEC)

We are a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. We are focused on developing an emerging pipeline of next generation therapies that target the DNA Damage Response (DDR) network. We have a highly experienced management team with a proven track record of success in oncology drug development. We are an ambitious company, oriented towards achieving the successful registration and commercialization of our product candidates. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). Chk1 is a key regulator of cell cycle progression and the DDR replication stress response.  ... More ...  

Risk Grade

Where does SRRA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.45
Open Date:
Jun. 22, 2018
Close Price:
$ 3.30
Close Date:
Jun. 22, 2018

Consensus Recommendation

Analyst Info